Hepatic PPARs: Their role in liver physiology, fibrosis and treatment

Current Medicinal Chemistry

Volumn 20, Issue 27, 2013, Pages 3370-3396

  Zardi, E M ^a   Navarini, L ^a   Sambataro, G ^a   Piccinni, P ^a   Sambataro, F M ^a   Spina, C ^a   Dobrina, A ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Antifbrotic therapy; Cytokines; Genes; HSCs; Ligands; Liver fibrosis; Microcirculation; PPARs; Transcription factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; BEZAFIBRATE; CIGLITAZONE; CIPROFIBRATE; CLOFIBRATE; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GW 1514; GW 610742; HYDROCORTISONE; ICOSAPENTAENOIC ACID; KD 3010; NETOGLITAZONE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PIRINIXIC ACID; RIVOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOGENESIS; ALCOHOL LIVER DISEASE; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; APOPTOSIS; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; CONFORMATIONAL TRANSITION; CPG ISLAND; DIET SUPPLEMENTATION; DNA METHYLATION; ENDOTHELIUM CELL; EXON SKIPPING; FATTY ACID OXIDATION; FATTY LIVER; FIBROGENESIS; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIVER FIBROSIS; LIVER INJURY; LIVER ISCHEMIA; LIVER SINUSOID; MICROCIRCULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

EID: 84883309760     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990136     Document Type: Review

References (289)

1. Tugwood, J.D.; Issemann, I.; Anderson, R.G.; Bundell, K.R.; McPheat, W.L.; Green, S. The mouse peroxisome proliferatoractivated receptor recognizes a response element in the 5́ flanking sequence of the rat acyl CoA oxidase gene. EMBO J., 1992, 11 (2), 433-439.
2. Auwerx, J.; Baulieu, E.; Beato, M.; Becker-Andre, M.; Burbach, P.H.; Camerino, G.; Chambon, P.; Cooney, A.; Dejean, A.; Dreyer, C.; Evans, R.M.; Gannon, F.; Giguere, V.; Gronemeyer, H.; Gustafsson, J.A.; Laudet, V.; Lazar, M.A.; Mangelsdorf, D.J.; Millbrandt, J.; Milgrom, E.; Moore, D.D.; O'Malley, B.; Parker, M.; Parker, K.; Perimann, T.; Pfahl, M.; Rosenfeld, M.G.; Samuels, H.; Schutz, G.; Sladek, F.M.; Stunnenberg, H.G.; Spedding, M.; Thummel, C.; Tsai, M.J.; Umesono, K.; Vennstrom, B.; Wahli, W.; Weinberg, C.; Willson, T.M.; Yamamoto, K. A unified nomenclature system for the nuclear receptor superfamily. Cell, 1999, 97 (2), 161-163.
3. Francis, G.A.; Fayard, E.; Picard, F.; Auwerx, J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol., 2003, 65, 261-311.
4. Miyahara, T.; Schrum, L.; Rippe, R.; Xiong, S.; Yee, H.F. Jr; Motomura, K.; Anania, F.A.; Willson, T.M.; Tsukamoto, H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem., 2000, 275(46), 35715-35722.
5. Zardi, E.M.; Dobrina, A.; Ambrosino, G.; Margiotta, D.; Polistina, F.; Afeltra, A. New therapeutic approaches to liver fibrosis: a practicable route? Curr. Med. Chem., 2008, 15 (16), 1628-1644.
6. Zhang, C.; Guo, X.; Jiang, G.; Zhang, L.; Yang, Y.; Shen, F.; Wu, M.; Wei, L. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int. J. Cancer, 2008, 123, 998-1004.
7. Harder, J.; Opitz, O.G.; Brabender, J.; Olschewski, M.;, Blum, H.E.; Nomoto, S.; Usadel, H. Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int. J. Cancer, 2008, 122, 2800-2804.
8. Mann, J.; Chu, D.C.K.; Maxwell, A.; Oakley, F.; Zhu, N.L.; Tsukamoto, H.; Mann, D.A. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology, 2010, 138, 705-714.
9. Tsukamoto, H.; Zhu, N.L.; Asahina, K.; Mann, D.A.; Mann, J. Epigenetic cell fate regulation of hepatic stellate cells. Hepatol. Res., 2011, 41, 675-682.
10. Matsumoto, K.; Taniura, H.; Uetsuki, T.; Yoshikawa, K. Necdin acts as a transcriptional repressor that interacts with multiple guanosine cluisters. Gene, 2001, 272, 173-179.
11. Perugorria, M.J.; Wilson, C.L.; Zeybel, M.; Walsh, M.; Amin, S.; Robinson, S.; With, S.A.; Burt, A.D.; Oakley, F.; Tsukamoto, H.; Mann, D.A.; Mann, J. Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. Hepatology, 2012, 56, 1129-1139.
12. Mann, J.; Oakley, F.; Akiboye, F.; Elsharkawi, A.; Thorne, A.W.; Mann, D.A. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis, Cell Death Differ., 2006, 14, 275-285.
13. Quin, L.; Han, Y.P. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am. J. Pathol., 2010, 177, 1915-1928.
14. Mann, J.; Xu, X.; Oakley, F.; Maxwell, A.; Elsharkawi, A.M.; Mann, D.A.; Burt, A.D. Epigenetically inherited resistance to liver fibrosis. Hepatology, 2009, 50, 849A-850A.
15. Haussinger, D.; Kubitz, R.; Reinehr, R.; Bode, J.G.; Schliess, F. Molecular aspects of medicine: from experimental to clinical hepatology. Mol. Aspects Med., 2004, 25 (3), 221-360.
16. Sung, C.K.; She, H.; Xiong, S.; Tsukamoto, H. Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells. Am. J. Physiol. Gastrointest Liver Physiol., 2004, 286 (5), G722-G729.
17. Eng, F.J.; Friedman, SL. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am. J. Physiol. Gastrointest Liver Physiol., 2000, 279 (1), G7-G11.
18. Dowell, P.; Peterson, V.J.; Zabriskie, T.M.; Leid, M. Ligandinduced peroxisome proliferator-activated receptor alpha conformational change. J. Biol. Chem., 1997, 272 (3) 2013-2020.
19. Marra. F.; Efsen, E.; Romanelli, R.G.; Caligiuri, A.; Pastacaldi, S.; Batignani, G.; Bonacchi, A.; Caporale, R.; Laffi, G.; Pinzani, M.; Gentilini, P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology, 2000, 119 (2), 466-478.
20. Owen, G.I.; Zelent, A. Origins and evolutionary diversification of nuclear receptor superfamily. Cell. Mol. Life Sci., 2000, 57 (5), 809-827.
21. Werman, A.; Hollenberg, A.; Solanes, G.; Bjørbaek, C.; Vidal-Puig, A.J.; Flier, J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARγ). J. Biol. Chem., 1997, 272 (32), 20230-20235.
22. Shao, D.; Rangwala, S.M.; Bailey, S.T.; Krakow, S.L.; Reginato, M.J.; Lazar M.A. Interdomain communication regulating ligand binding by PPAR-gamma. Nature, 1998, 396 (6709) 377-380.
23. Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature, 1998, 395 (6698), 137-143.
24. Berger, J.; Moller, D.E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
25. Uppenberg, J.; Svensson, C.; Jaki, M.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem., 1998, 273(47), 31108-31112.
26. Xu, H.E.; Lambert, M.H.; Montana, V.G.; Plunket, K.D.; Moore, L.B.; Collins, J.L.; Oplinger, J.A.; Kliewer, S.A.; R.T. Gampe, R.T.Jr.; McKee, D.D.; Moore, J.T.; Willson, T.M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors, Proc. Natl. Acad. Sci., 2001, 98, 13919-13924.
27. Renaud, J.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal structure of the RAR-[gamma] ligand-binding domain bound to all-trans retinoic acid. Nature, 1995, 378, 681-689.
28. Hamuro, Y.; Coales, S.J.; Morrow, J.A.; Molnar, K.S.; Tuske, S.J.; Southern, M.R.; Griffin, P.R. Hydrogen/deuterium-exchange (H/DEx) of PPARgamma LBD in the presence of various modulators. Protein Sci., 2006, 15, 1883-1892.
29. Uppenberg, J.; Svensson, C.; Jaki, M.; Bertilsson, G.; Jendeberg, L.; Berkenstam, A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamm. J. Biol. Chem., 1998, 273, 31108-31112.
30. Nagy, L.; Schwabe, J.W.R. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci., 2004, 29, 317-324.
31. Molnàr, F.; Matilainen, M.; Carlberg, C.; Structural determinants of the agonist-independent association of human peroxisome proliferator- activated receptors with coactivators, J. Biol. Chem., 2005, 280, 26543-26556.
32. Michalik, L.; Zoete, V.; Krey, G.; Grosdidier, A.; Gelman, L.; Chodanowski, P.; Feige, J.N.; Desvergne, B.; Wahli, W.; Michielin, M. Combined simulation and mutagenesis analyses of PPAR[alpha] AF-2 unveil the basis of helix 12 dynamics. J. Biol. Chem., 2007, 382 (13), 9666-9677.
33. Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferatoractivated receptor-gamma, Nature, 1998, 395, 137-143.
34. Xu, H.E.; Stanley, T.B.; Montana, V.G.; Lambert, M.H.; Shearer, B.G.; Cobb, J.E.; McKee, D.D.; Galardi, C.M.; Plunket, K.D.; Nolte, R.T.; Parks, D.J.; Moore, J.T.; Kliewer, S.A.; Willson, T.M.; Stimmel, J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR[alpha], Nature, 2002, 415, 813-817.
35. Sher, T.; Yi, H.F.; McBride, O.W.; Gonzalez, F.J. cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry, 1993, 32 (21), 5598-5604.
36. Pyper, S.R.; Viswakarma, N.; Yu, S.; Reddy, J.K. PPARα: energy combustion, hypolipidemia, inflammation and cancer". Nucl. Recept. Signal., 2010, 8, e002.
37. Pineda Torra, I.; Jamshidi, Y.; Flavell, D.M.; Fruchart, J.C.; Staels, B. Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol. Endocrinol., 2002, 16(5), 1013-1028.
38. Genini, D.; Carbone, G.M.; Catapano, C.V. Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res., 2008, 2008:195065.
39. El Kebbaj, Z.; Andreoletti, P.; Mountassif, D.; Kabine, M.; Schohn, H.; Dauça, M.; Latruffe, N.; El Kebbaj, M.S.; Cherkaoui-Malki, M. Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal. Endocrinology, 2009, 150 (3), 1192-1201.
40. Juge-Aubry, C.E.; Hammar, E.; Siegrist-Kaiser, C.; Pernin, A.; Takeshita, A.; Chin, W.W.; Burger, A.G.; Meier, C.A. Regulation of the transcriptional activity of the peroxisome proliferatoractivated receptor alpha by phosphorylation of a ligandindependent trans-activating domain. J. Biol. Chem., 1999, 274(15), 10505-10510.
41. Barger, P.M.; Browning, A.C.; Garner, A.N.; Kelly, D.P.J. p38 mitogen-activated protein kinase activates peroxisome proliferatoractivated receptor alpha: a potential role in the cardiac metabolic stress response. J Biol. Chem., 2001, 276 (48) 44495-44501.
42. Blanquart, C.; Mansouri, R.; Paumelle, R.; Fruchart, J.C.; Staels, B.; Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha", Mol. Endocrinol., 2004, 18 (8), 1906-1918.
43. Kliewer, S.A.; Umesono, K.; Noonan, D.J.; Heyman, R.A.; Evans, R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 1992, 358 (6389), 771-774.
44. DiRenzo, J.; Söderstrom, M.; Kurokawa, R.; Ogliastro, M.H.; Ricote, M.; Ingrey, S.; Hörlein, A.; Rosenfeld, M.G.; Glass, C.K. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol. Cel. Biol., 1997, 17 (4), 2166-2176.
45. Van Der Meer, D.L.; Degenhardt, T.; Väisänen, S.; de Groot, P.J.; Heinäniemi, M.; de Vries, S.C.; Müller, M.; Carlberg, C.; Kersten, S. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids Res., 2010, 38 (9), 2839-2850.
46. Jow, L.; Mukherjee, R. The human peroxisome proliferatoractivated receptor (PPAR) subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors. J. Biol. Chem., 1995, 270(8), 3836-3840.
47. Feige, J.N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res., 2006, 45 (2), 120-159.
48. Glass, C.K.; Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev., 2000, 14 (2), 121-141.
49. Evans, R.M.; Barish, G.D.; Wang, Y.X. PPARs and the complex journey to obesity. Nat. Med., 2004, 10 (4), 355-361.
50. Mello, T.; Polvani, S.; Galli, A. Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease. PPAR Res., 2009, 2009:748174.
51. Ide, T.; Shimano, H.; Yoshikawa, T.; Yahagi, N.; Amemiya-Kudo, M.; Matsuzaka, T.; Nakakuki, M.; Yatoh, S.; Iizuka, Y.; Tomita, S.; Ohashi, K.; Takahashi, A.; Sone, H.; Gotoda, T.; Osuga, J.; Ishibashi, S.; Yamada, N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signalling. Mol. Endocrinol., 2003, 17 (7), 1255-1267.
52. Deng, Q.G.; She, H.; Cheng, J.H.; French, S.W.; Koop, D.R.; Xiong, S.; and Tsukamoto, H. Steatohepatitis induced by intragastric overfeeding in mice", Hepatology, 2005, 42 (4), 905-914.
53. Hebbachi, A.M.; Knight, B.L.; Wiggins, D.; Patel, D.D.; Gibbons, G.F. Peroxisome proliferator-activated receptor alpha deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptoralpha", J. Biol. Chem., 2008, 283 (8), 4866-4876.
54. Reddy, J.K.; Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Ann. Rev. Nutr., 2001, 21, 193-230.
55. Hostetler, H.A.; Petrescu, A.D.; Kier, A.B.; Schroeder, F. Peroxisome proliferator-activated receptor α interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem., 2005, 280, (19), 18667-18682.
56. Chakravarthy, M.V.; Lodhi, I.J.; Yin, L.; Malapaka, R.R.; Xu, H.E.; Turk, J.; Semenkovich, C.F. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell, 2009, 138 (3), 476-488.
57. Lamaziere, A.; Wolf, C. Phosphatidylcholine and PPARα: a relevant connection in liver disease?. Gastroentérol. Clin. Biol., 2010, 34 (4-5), 250-251.
58. Yamauchi, T.; Kamon, J.; Ito, Y.; Tsuchida, A.; Yokomizo, T.; Kita, S.; Sugiyama, T.; Miyagishi, M.; Hara, K.; Tsunoda, M.; Murakami, K.; Ohteki, T.; Uchida, S.; Takekawa, S.; Waki, H.; Tsuno, N.H.; Shibata, Y.; Terauchi, Y.; Froguel, P.; Tobe, K.; Koyasu, S.; Taira, K.; Kitamura, T.; Shimizu, T.; Nagai, R; Kadowaki, P.T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423 (6949), 762-769.
59. Staels, B.; Vu-Dac, N.; Kosykh, V.; Saladin, R.; Fruchart, J.C.; Dallongeville, J.; Auwerx, J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J. Clin. Invest., 1995, 95 (2), 705-712.
60. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.M.; Heyman, R.; Briggs M.; Deeb, S.; Staels, B.; Auwerx, J. PPAR alpha and PPAR gamma activators direct a tissue-specific transcriptional response via aPPREin the lipoprotein lipase gene. EMBO J., 1996, 15 (19), 5336-5348.
61. Vu-Dac, N.; Chopin-Delannoy, S.; Gervois, P.; Bonnelye, E.; Martin, G.; Fruchart, J.C.; Laudet, V.; Staels, B. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the speciesspecific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem., 1998, 273 (40), 25713-25720.
62. Devchand, P.R.; Keller, H.; Peters, J.M.; Vazquez, M.; Gonzalez, F.J.; Wahli, W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature, 1996, 384, (6604), 39-43.
63. Ota, T.; Suzuki, Y.; Nishikawa, T.; Otsuki, T.; Sugiyama, T.; Irie, R.; Wakamatsu, A.; Hayashi, K.; Sato, H.; Nagai, K.; Kimura, K.; Makita, H.; Sekine, M.; Obayashi, M.; Nishi, T.; Shibahara, T.; Tanaka, T.; Ishii, S.; Yamamoto, J.; Saito, K.; Kawai, Y.; Isono, Y.; Nakamura, Y.; Nagahari, K.; Murakami, K.; Yasuda, T.; Iwayanagi, T.; Wagatsuma, M.; Shiratori, A.; Sudo, H.; Hosoiri, T.; Kaku, Y.; Kodaira, H.; Kondo, H.; Sugawara, M.; Takahashi, M.; Kanda, K.; Yokoi, T.; Furuya, T.; Kikkawa, E.; Omura, Y.; Abe, K.; Kamihara, K.; Katsuta, N.; Sato, K.; Tanikawa, M.; Yamazaki, M.; Ninomiya, K.; Ishibashi, T.; Yamashita, H.; Murakawa, K.; Fujimori, K.; Tanai, H.; Kimata, M.; Watanabe, M.; Hiraoka, S.; Chiba, Y.; Ishida, S.; Ono, Y.; Takiguchi, S.; Watanabe, S.; Yosida, M.; Hotuta, T.; Kusano, J.; Kanehori, K.; Takahashi-Fujii, A.; Hara, H.; Tanase, T.O.; Nomura, Y.; Togiya, S.; Komai, F.; Hara, R.; Takeuchi, K.; Arita, M.; Imose, N.; Musashino, K.; Yuuki, H.; Oshima, A.; Sasaki, N.; Aotsuka, S.; Yoshikawa, Y.; Matsunawa, H.; Ichihara, T.; Shiohata, N.; Sano, S.; Moriya, S.; Momiyama, H.; Satoh, N.; Takami, S.; Terashima, Y.; Suzuki, O.; Nakagawa, S.; Senoh, A.; Mizoguchi, H.; Goto, Y.; Shimizu, F.; Wakebe, H.; Hishigaki, H.; Watanabe, T.; Sugiyama, A.; Takemoto, M.; Kawakami, B.; Yamazaki, M.; Watanabe, K.; Kumagai, A.; Itakura, S.; Fukuzumi, Y.; Fujimori, Y.; Komiyama, M.; Tashiro, H.; Tanigami, A.; Fujiwara, T.; Ono, T.; Yamada, K.; Fujii, Y.; Ozaki, K.; Hirao, M.; Ohmori, Y.; Kawabata, A.; Hikiji, T.; Kobatake, N.; Inagaki, H.; Ikema, Y.; Okamoto, S.; Okitani, R.; Kawakami, T.; Noguchi, S.; Itoh, T.; Shigeta, K.; Senba, T.; Matsumura, K.; Nakajima, Y.; Mizuno, T.; Morinaga, M.; Sasaki, M.; Togashi, T.; Oyama, M.; Hata, H.; Watanabe, M.; Komatsu, T.; Mizushima-Sugano, J.; Satoh, T.; Shirai, Y.; Takahashi, Y.; Nakagawa, K.; Okumura, K.; Nagase, T.; Nomura, N.; Kikuchi, H.; Masuho, Y.; Yamashita, R.; Nakai, K.; Yada, T.; Nakamura, Y.; Ohara, O.; Isogai, T.; Sugano, S. Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat. Genet., 2004, 36 (1), 40-45.
64. Schmidt, A.; Endo, N.; Rutledge, S.J.; Shinar, D.; Rodan, G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol., 1992, 6 (10), 1634-1641.
65. Keller, H.; Dreyer, C.; Medin, J.; Mahfoudi, A.; Ozato, K.; Wahli, W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferatoractivated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. U.S.A., 1993, 90 (6), 2160-2164.
66. Tan, N.S.; Michalik, L.; Noy, N.; Yasmin, R.; Pacot, C.; Heim, M.; Flühmann, B.; Desvergne, B.; Wahli, W. "Critical roles ofPPAR beta/delta in keratinocyte response to inflammation", Genes Dev., 2001, 15 (24), 3263-3277.
67. Yu, S.; Reddy, J.K. Transcription coactivators for peroxisome proliferatoractivated receptors. Biochem. Biophys. Acta, 2007, 1771 (8), 936-951.
68. Girroir, E.E.; Hollingshead, H.E.; He, P.; Zhu, B.; Perdew, G.H.; Peters, J.M.; Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice", Biochem. Biophys. Res. Commun., 2008, 371 (3), 456-461.
69. Hellemans, K.; Rombouts, K.; Quartier, E.; Diettiè, AS.; Knorr, A.; Michalik, L.; Rogiers, V.; Schuit, F.; Wahli, W.; Geerts, A. PPARβ regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation. J. Lipid Res., 2003, 44 (2), 280-295.
70. Hellemans, K.; Michalik, L.; Dittie, A.; Knorr, A.; Rombouts, K.; De Jong, J.; Heirman, C.; Quartier, E.; Schuit, F.; Wahli, W.; Geerts, A. Peroxisome proliferator-activated receptor-β signaling contributes to enhanced proliferation of hepatic stellate cells. Gastroenterology, 2003, 124 (1), 184-201.
71. Shan, W.; Palkar, PS.; Murray, IA.; McDevitt, EI.; Kennett, MJ.; Kang, BH.; Isom, HC.; Perdew, GH.; Gonzalez, FJ.; Peters, JM. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci., 2008, 105 (2), 418-428.
72. Liu, S.; Hatano, B.; Zhao, M.; Yen, C.C.; Kang, K.; Reilly, S.M.; Gangl, M.R.; Gorgun, C.; Balschi, J.A.; Ntambi, J.M.; Lee, C.H. Role of peroxisome proliferator activated receptor {delta}/{beta} in hepatic metabolic regulation", J. Biol. Chem., 2011, 286 (2), 1237-1247.
73. Takahashi, S.; Tanaka, T.; Sakai, J. New therapeutic target for metabolic syndrome: PPAR δ. Endocr. J., 2007, 54 (3), 347-357.
74. Odegaard, J. I.; Chawla, A. Alternative macrophage activation and metabolism. Annu. Rev. Pathol., 2011, 6, 275-297.
75. Akiyama, TE.; Lambert, G.; Nicol, CJ.; Matsusue, K.; Peters, JM.; Brewer, HB. Jr.; Gonzalez, FJ. Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J. Biol. Chem., 2004, 279 (20), 20874-20881.
76. Narkar, V.A.; Downes, M.; Yu, R.T.; Embler, E.; Wang, Y.X.; Banayo, E.; Mihaylova, M.M.; Nelson, M.C.; Zou, Y.; Juguilon, H.; Kang, H.; Shaw, R.J.; Evans, R.M. AMPK and PPARdelta agonists are exercise mimetics. Cell, 2008, 134 (3), 405-415.
77. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med., 2005, 11 (2), 183-190.
78. Shan, W.; Palkar, P.S.; Murray, I.A.; McDevitt, E.I.; Kennett, M.J.; Kang, B.H.; Isom, H.C.; Perdew, G.H.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci., 2008, 105 (2), 418-428.
79. Klimcakova, E.; Moro, C.; Mazzucotelli, A.; Lolmède, K., Viguerie, N; Galitzky J.; Stich, V.; Langin, D. Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem. Biophys. Res. Commun., 2007, 358 (3), 897-902.
80. Kang, K.; Reilly, S.M.; Karabacak, V.; Gangl, M.R.; Fitzgerald, K.; Hatano, B.; Lee, C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab., 2008, 7 (6), 485-495.
81. Greene, M.E.; Blumberg, B.; McBride, O.W.; Yi, H.F.; Kronquist, K.; Kwan, K.; Hsieh, L.; Greene, G.; Nimer, S.D.Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr.,2005, 4, (4-5) 281-299.
82. Fajas, L.; Auboeuf, D.; Raspé, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M.R.; Staels, B.; Vidal, H.; Auwerx, J. The organization, promoter analysis, and expression of the human PPAR-gamma gene". J. Biol. Chem., 1997, 272 (30), 18779-18789.
83. Fajas, L.; Fruchart, J.C.; Auverx, J. PPAR - gamma3 mRNA: a distinct PPAR-gamma mRNA subtype transcribed from an independent promoter. FEBS Lett., 1998, 438 (1-2), 55-60.
84. Sundvold, H.; Lien. S. Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem. Biophys. Res. Commun., 2001, 287 (2), 383-390.
85. Zhu, Y.; Qi, C.; Korenberg, J.R.; Chen, X.N.; Noya, D.; Rao, M.S.; Reddy, J.K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR-gamma) gene: Alternative promoter use and different splicing yield two mPPAR-gamma isoforms. Proc. Natl. Acad. Sci. U.S.A., 1995, 92 (17) 7921-7925.
86. Shafiei, MS.; Shetty, S.; Scherer, PE.; Rockey, DC. Adiponectin regulation of stellate cell activation via PPARγ-dependent and -independent mechanisms. Am. J. Pathol., 2011, 178 (6), 2690-2699.
87. Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell, 1994, 79 (7), 1147-1156.
88. Altshuler, D.; Hirschhorn, J.N.; Klannemark, M.; Lindgren, C.M.; Vohl, M.C.; Nemesh, J.; Lane, C.R.; Schaffner, S.F.; Bolk, S.; Brewer, C.; Tuomi, T.; Gaudet, D.; Hudson, T.J.; Daly, M.; Groop, L.; Lander, E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet., 2000, 26 (1), 76-80.
89. Rangwala, S.M.; Rhoades, B.; Shapiro, J.S.; Rich, A.S.; Kim, J.K.; Shulman, G.I.; Kaestner, K.H.; Lazar, M.A. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev. Cell, 2003, 5 (4), 657-663.
90. Gavrilova, O.; Haluzik, M.; Matsusue, K.; Cutson, J.J.; Johnson, L.; Dietz, K.R.; Nicol, C.J.; Vinson, C.; Gonzalez, F.J.; Reitman, M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem., 2003, 278 (36), 34268-34276.
91. Potter, J.J.; Womack, L.; Mezey, E.; Anania, F.A. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem. Biophys. Res. Commun., 1998, 244 (1) 178-182.
92. Potter, J.J.; Mezey, E. acetaldehyde increases endogenous adiponectin and fibrogenesis in hepatic stellate cells but exogenous adiponectin inhibits fibrogenesis. Alcohol. Clin. Exp. Res., 2007, 31 (12), 2092-2100.
93. Bertolani, C.; Sancho-Bru, P.; Failli, P.; Bataller, R.; Aleffi, S.; DeFranco, R.; Mazzinghi, B.; Romagnani, P.; Milani, S.; Ginés, P.; Colmenero, J.; Parola, M.; Gelmini, S.; Tarquini, R.; Laffi, G.; Pinzani, M.; Marra, F. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory action in hepatic stellate cells. Am. J. Pathol., 2006, 169 (6), 2042-2053.
94. Guimarães, E.L.; Francesco, M.F.; Andrade, C.M.; Guaragna, R.M.; Borojevic, R.; Margis, R.; Bernard, E.A.; Guma, F.C. Hepatic stellate cell line modulates lipogenic transcription factors. Liver Int., 2007, 27(9), 1255-1264.
95. Yamada, M.; Blaner, W.S.; Soprano, D.R.; Dixon, J.L.; HKjeldbye, H.M.; Goodman, D.S. biochemical characteristics of isolated rat liver stellate cells. Hepatology, 1987, 7 (6), 1224-1229.
96. Spiegelman, B.M.; Flier, J.S. Adipogenesis and obesity: rounding out the big picture. Cell, 1996, 87 (3), 377-389.
97. Galli, A.; Crabb, D.W.; Ceni, E.; Salzano, R.; Mello, T.; Svegliati-Baroni, G.; Ridolfi, F.; Trozzi, L.; Surrenti, C.; Casini, A. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002, 122 (7), 1924-1940.
98. Hazra, S.; Xiong, S.; Wang, J.; Rippe, R.A.; Krishna, V.; Chatterjee, K.; Tsukamoto, H. Peroxisome proliferator activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J. Biol. Chem., 2004, 279 (12), 11392-11401.
99. Mandard, S.; Müller, M.; Kersten, S. Peroxisome proliferator- activated receptor alpha target genes. Cell. Mol. Life Sci., 2004, 61 (4), 393-416.
100. Moriya, T.; Naito, H.; Ito, Y.; Nakajima, T. "Hypotesis of seven balances": molecular mechanisms behind alcoholic liver diseases and association with PPAR-alpha. J. Occup. Health, 2009, 51 (5), 391-403.
101. Lieber, C.S. Alcoholic fatty liver: its pathogenesis and mechanism of progressione to inflammation and fibrosis. Alcohol, 2004, 34 (1), 9-19.
102. Wu, D.; Zhai, Q.; Shi, X. Alcohol-induced oxidative stress and cell responses. J. Gastroenterol. Hepatol., 2006, 21 (3), S26-S29.
103. Wan, Y.J.; Morimoto, M.; Thurman, R.G.; Bojes, H.K.; French, S.W. Expression of the peroxisome proliferator-activated receptor genes is decreased in experimental alcoholic liver disease. Life Sci., 1995, 56 (5), 307-317.
104. Galli, A.; Pinaire, J.; Fischer, M.; Dorris, R.; Crabb, D.W. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J. Biol. Chem., 2001, 27 (1), 68-75.
105. Toyama, T.; Nakamura, H.; Harano, Y.; Yamauchi, N.; Morita, A.; Kirishima, T.; Minami, M.; Itoh, Y.; Okanoue, T. PPARalpha ligands activated antioxidant enzymes and suppress hepatic fibrosis in rats". Biochem. Biophys. Res. Commun., 2004, 324 (2), 697-704.
106. Inoue, I.; Goto, S.; Matsunaga, T.; Nakajima, T.; Awata, T.; Hokari, S.; Komoda, T.; S. Katayama, S. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+suporoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism, 2001, 50 (1), 3-11.
107. Hanck, C.; Rossol, S.; Böcker, U.; Tokus, M.; Singer, M.V. Presence of plasma endotoxin is correlated with tumor necrosis factor receptor levels and disease activity in alcoholic cirrhoisis. Alcohol Alcohol., 1998, 33 (6), 606-608.
108. Fujimoto, M.; Uemura, M.; Nakatani, Y.; Tsujita, S.; Hoppo, K.; Tamagawa, T.; Kitano, H.; Kikukawa, M.; Ann, T.; Ishii, Y.; Kojima, H.; Sakurai, S.; Tanaka, R.; Namisaki, T.; Noguchi, R.; Higashino, T.; Kikuchi, E.; Nishimura, K.; Takaya, A.; Fukui, H. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol. Clin. Exp. Res., 2000, 24 (4), 48S-54S.
109. A. Parlesak, A.; C. Schäfer, C.; T. Schütz, T.; J.C. Bode, J.C.; Bode, C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J. Hepatol., 2000, 32 (5), 742-747.
110. Urbaschek, R.; McCuskey, R.S.; Rudi, V.; Becker, K.P.; Stickel, F.; Urbaschek, B.; Seitz, H.K. Endotoxin, endotoxin-neutralizingcapacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol. Clin. Exp. Res., 2001, 25 (2), 261-268.
111. Rao, R.K.; Seth, A.; Sheth, P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 286 (6) G881-G884.
112. Keshavarzian, A.; Fields, J.Z.; Vaeth, J.; Holmes, E.W. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am. J. Gastroenterol., 1994, 89 (12), 2205-2011.
113. Keshavarzian, A.; Holmes, E.W.; Patel, M.; Iber, F.; Fields, J.Z.; Pethkar, S. Leaky gur in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am. J. Gastroenterol., 1999, 94 (1), 200-207.
114. Nakajima, T.; Kamijo, Y.; Tanaka, N.; Sugiyama, E.; Tanaka, E.; Kiyosawa, K.; Fukushima, Y.; Peters, J.M.; Gonzalez, F.J.; Aoyama, T. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology, 2004, 40 (4), 972-980.
115. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I.P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J.C.; Najib, K.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells in inhibited by PPARalpha but not PPAR-gamma activators. Nature, 1998, 393 (6687) 790-793.
116. Marx, N.; Sukhova, G.K.; Collins, T.; Libby, P.; Plutzky, J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation, 1999, 99 (24), 3125-3131.
117. Lee, SS.; Pineau, T.; Drago, J.; Lee, AJ.; Owens, JW.; Kroetz, DL.; Fernandez-Salguero, PM.; Westphal, H.; Gonzalez, FJ. Targeted disruption of the alpha isoform of the peroxisome proliferator activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol., 1995, 15 (6), 3012-3022.
118. Costet, P.; Legendre, C.; More, J.; Edgar, A.; Galtier, P.; Pineau, T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem., 1998, 273 (45), 29577-29585.
119. Reddy, JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281 (6), G1333-G1339.
120. Cheng, Y.; Dharancy, S.; Malapel, M.; Desreumaux, P. Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoylacyl-CoA transferase 1A. World J. Gastroenterol., 2005, 11 (48), 7591-7596.
121. Negro, F.; Sanyal, AJ. Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data. Liver Int., 2009, 29 (2), 26-37.
122. Svegliati-Baroni, G.; Ridolfi, F.; Di Sario, A.; Casini, A.; Marucci, L.; Gaggiotti, G.; Orlandoni, P.; Macarri, G.; Perego, L.; Benedetti, A.; Folli, F. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology, 1999, 29 (6), 1743-1751.
123. Marra, F.; Gastaldelli, A.; Baroni, GS.; Tell, G.; Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med., 2008, 14 (2), 72-81.
124. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature, 2000, 405 (6785), 421-424.
125. Trifillieff, A.; Bench, A.; Hanley, M.; Bayley, D.; Campbell, E.; Whittaker, P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-indipendent effect. Brit. J. Pharmacol., 2003, 139 (1), 163-171.
126. Scherer, P.E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes". J. Biol. Chem., 1995, 270 (45), 26746-26749.
127. You, M.; Crabb, D.W. Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287 (1), G1-G6.
128. Ouchi, N.; Nihara, S.; Funahashi, T.; Mutsuzawa, Y.; Walsh, K. Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol., 2003, 14 (6), 561-566.
129. Berg, A.H.; Combs, T.P.; Du, X.; Brownlee, M.; Scherer, P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med., 2001, 7 (8), 947-953.
130. Haluzík, M.; Parízková, J.; Haluzík, M.M. Adiponectin and its role in the obesity-induced insulin resistance and related complications". Physiol. Res., 2004, 53 (2), 123-129.
131. Matsuzawa, Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Ateroscler. Suppl., 2005, 6 (2), 7-14.
132. Xu, A.; Wang, Y.; Keshaw, H.; Xu, L.Y.; Lam, K.S.; Cooper, G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", J. Clin. Invest., 2003, 112 (1), 91-100.
133. You, M.; Considine, R.V.; Leone, T.C.; Kelly, D.P.; Crabb, D.W. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology, 2005, 42 (3), 568-577.
134. Shklyaev, S.; Aslanidi, G.; Tennant, M.; Prima, V.; Kohlbrenner, E.; Kroutov, V.; Campbell-Thompson, M.; Crawford, J.; Shek, E.W.; Scarpace, P.J.; Zolotukhin, S. Sustained peripheral expression of transgene adiponectin offsets the development of dietinduced obesity in rats. Proc. Natl. Acad. Sci. U.S.A., 2003, 100 (24), 14217-14222.
135. Czaja, M.J. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology, 2004, 40 (1), 19-22.
136. Masaki, T.; Chiba, S.; Tatsukawa, H.; Yasuda, T.; Noguchi, H.; Seike, M.; Yoshimatsu, H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology, 2004, 40 (1), 177-184.
137. Oliver, W.R.Jr.; Shenk, J.L.; Snaith, M.R.; Russell, C.S.; Plunket, K.D.; Bodkin, N.L.; Lewis, M.C.; Winegar, D.A.; Sznaidman, M.L.; Lambert, M.H.; Xu, H.E.; Sternbach, D.D.; Kliewer, S.A.; Hansen, B.C.; Wilson, T.M. A selective peroxisome proliferatoractivated receptor delta agonist promotes reverse cholesterol transport". Proc. Natl. Acad. Sci. U.S.A., 2001, 98 (9) 5306-5311.
138. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R.X.; Tachibana, K.; Watanabe, Y.; Uchiyama, Y.; Sumi, K.; Iguchi, H.; Ito, S.; Doi, T.; Hamakubo, T.; Naito, M.; Auwerx, J.; Yanagisawa, M.; Kodama, T.; Sakai, J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome", Proc. Natl Acad. Sci. U.S.A., 2003, 100 (26) 15924-15929.
139. Wang, Y.X.; Lee, C.H.; Tiep, S.; Yu, R.T.; Ham, J.; Kang, H.; Evans, R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell, 2003, 113 (2), 159-170.
140. Qatanani, M.; Lazar, M.A. Mechanisms of obesity-associated insulin resistace: many choices on the menu Genes Dev., 2007, 21 (12), 1443-1455.
141. Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Red Eagle, A.; Vats, D:; Morel, C.R.; Goforth, M.H.; Subramanian, V.; Mukundan, L.; Ferrante, A.W.; Chawla, A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab., 2008, 7 (6), 496-507.
142. Yamauchi, T.; Nio, Y.; Maki, T.; Kobayashi, M.; Takazawa, T.; Iwabu, M.; Okada-Iwabu, M.; Kawamoto, S.; Kubota, N.; Kubota, T.; Ito, Y.; Kamon, J.; Tsuchida, A.; Kumagai, K.; Kozono, H.; Hada, Y.; Ogata, H.; Tokuyama, K.; Tsunoda, M.; Ide, T.; Muramaki, K.; Awazawa, M.; Takamoto, I.; Froguel, P.; Hara, K.; Tobe, K.; Nagai, R.; Ueki, K.; Kadowaki, T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions". Nat. Med., 2007, 13 (3), 332-339.
143. Horike, N.; Sakoda, H.; Kushiyama, A.; Ono, H.; Fujishiro, M.; Kamata, H.; Nishiyama, K.; Uchijima, Y.; Kurihara, Y.; Kurihara, H.; Asano. T. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver". J. Biol. Chem., 2008, 283 (49), 33902-33910.
144. Zhang, F.; Lu, Y.; Zheng, S. Peroxisome proliferator-activated receptor-gamma cross-regulation of signaling events implicated in liver fibrogenesis. Cell. Signal., 2012, 24 (3), 596-605.
145. Hezra, S.; Miyahara, T.; Rippe, R.A.; Tsukamoto, H. PPAR gamma and hepatic stellate cells. Comp. Hepatol., 2004, 3 (1), S7.
146. She, H., Xiong, S.; Hazra, S.; Tsukamoto, H. Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem., 2005, 280 (6), 4959-4967.
147. Mann, J.; Oakley, F.; Akiboye, F.; Elsharkawy, A.; Thorne, A.W.; Mann, D.A. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis", Cell Death Differ., 2007, 14 (2), 275-285.
148. Lam, B.; Younossi, Z.M. Treatment options for nonalcoholic fatty liver disease. Therap. Adv. Gastroenterol., 2010, 3 (2), 121-137.
149. Seyhan, H.; Hamzavi, J.; Wiercinska, E.; Gressner, A.M.; Mertens, P.R.; Kopp, J.; Horch, R.S.; Breitkopf, K.; Dooley, S. Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. J. Cell. Mol. Med., 2006, 10 (4), 922-932.
150. Ghosh, A.K.; Bhattacharyya, S.; Lakos, G.; Chen, S.J.; Mori, Y.; Varga, J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum., 2004, 50 (4), 1305-1318.
151. George, J.; Tsutsumi, M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther., 2007, 14 (10), 790-803.
152. Bonner, J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev., 2004, 15 (4), 255-273.
153. Campbell, J.S.; Hughes, S.D.; Gilbertson, D.G.; Palmer, T.E.; Holdren, M.S.; Haran, A.C.; Odell, M.M.; Bauer, R.L.; Ren, H.P.; Haugen, H.S.; Yeh, M.M.; Fausto, N. Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma", Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (9), 3389-3394.
154. Borkham-Kamphorst, E.; Van Roeyen, C.R.; Ostendorf, T, Floege, J.; Gressner, A.M.; Weiskirchen, R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J.Hepatol., 2007, 46 (6), 1064-1074.
155. Galli, A.; Crabb, D.; Prince, D.; Ceni, E.; Salzano, R.; Surrenti, C.; Casini, A. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factorinduced proliferation of human hepatic stellate cells. Hepatology, 2000, 31 (1), 101-108.
156. Ghosh, S.S.; Gehr, T.W.; Ghosh, S.; Fakhry, I.; Sica, D.A.; Lyall, V.; Schoolwerth, A.C. PPAR-gamma ligand attenuates PDGFinduced mesangial cell proliferation: role of MAP kinase. Kidney Int., 2003, 64 (1) 52-62.
157. Nakamura, T.; Sakai, K.; Nakamura, T.; Matsumoto, K. Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol., 2011, 26 (1), 188-202.
158. Matsuda, Y.; Matsumoto, K.; Yamada, A.; Ichida, T.; Asakura, H.; Komoriya, Y.; Nishiyama, E.; Nakamura T. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology, 1997, 26 (1), 81-89.
159. Yasuda, H.; Imai, E.; Shiota, A.; Fujise, N.; Morinaga, T.; Higashio, K. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats". Hepatology, 1996, 24 (3), 636-642.
160. Xia, J.L.; Dai, C.; Michalopoulos, G.K.; Liu,Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol., 2006, 168 (5), 1500-1512.
161. Inagaki, Y.; Higashi, K.; Kushida, M.; Hong, Y.Y.; Nakao, S.; Higashiyama, R.; Moro, T.; Itoh, J.; Mikami, T.; Kimura, T.; Shiota, G.; Kuwabara, I.; Okazaki, I. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7". Gastroenterology, 2008, 134 (4), 1180-1190.
162. Jiang, J.G.; Johnson, C.; Zarnegar R. Peroxisome proliferatoractivated receptor gamma-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element. J. Biol. Chem., 2001, 276 (27), 25049-25056.
163. Doi, S.; Masaki, T.; Arakawa, T.; Takahashi, S.; Kawai, T.; Nakashima, A.; Naito, T.; Kohno, N.; Yorioka, N. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemiareperfusion injury". Transplantation, 2007, 84 (2), 207-213.
164. Aleffi, S.; Petrai, I; Bertolani, C.; Parola, M.; Colombatto, S.; Novo, E.; Vizzuti, F.; Anania, F.A.; Milani, S.; Rombouts, K.; Laffi, G.; Pinzani, M.; Marra, F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology, 2005, 42 (6), 1339-1348.
165. Choi, S.S.; Syn, W.K.; Karaca, G.F.; Omenetti, A.; Moylan, C.A.; Witek, R.P.; Agboola, K.M.; Jung, Y.; Michelotti, G.A.; Diehl, A.M. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J. Biol., 2010, 285 (47), 36551-36560.
166. Ikejima, K.; Honda, H.; Yoshikawa, M.; Hirose, M.; Kitamura, T.; Takei, Y.; Sato, N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology, 2001, 34 (2), 288-297.
167. Leclercq, I.A.; Farrella, G.C.; Schriemer, R.; Robertson, G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol., 2002, 37 (2), 206-213.
168. Ikejima, K.; Takei, Y.; Honda, H.; Hirose, M.; Yoshikawa, M.; Zhang, Y.J.; Lang, T.; Fukuda, T.; Yamashina, S.; Kitamura, T.; Sato, N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat", Gastroenterology, 2002, 122 (5), 1399-1410.
169. Zhou, Y.; Jia, X.; Wang, G.; Wang, X.; Liu, J. PI-3 K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol. Cell. Biochem., 2009, 325 (1-2), 31-139.
170. Zhou, Y.; Jia, X.; Qin, J.; Lu, C.; Zhu, H.; Li, X.; Han, X.; Sun, X. Lepin inhibits PPARgamma gene expression in hepatic stellate cells in the mouse model of liver damage. Mol. Cell. Endocrinol., 2010, 323 (2), 193-200.
171. Kamada, Y.; Tamura, S.; Kiso, S.; Matsumoto, H.; Saji, Y.; Yoshida, Y.; Fukui, K.; Maeda, N.; Nishizawa, H.; Nagaretani, H.; Okamoto, Y.; Kihara, S.; Miyagawa, J.; Shinomura, Y.; Funahashi, T.; Matsuzawa, Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology, 2003, 125 (6), 1796-1807.
172. Ding, X.; Saxena, N.K.; Lin, S.; Xu, A.; Srinivasan, S.; Anania, F.A. The roles of leptin and adiponectin: a novel paradigm in adipocyokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol., 2005, 166 (6), 1655-1669.
173. Adachi, M.; Brenner, D.A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology, 2008, 47 (2), 677-685.
174. Zhou, M.; Xu, A.; Tam, P.K.; Lam, K.S.; Chan, L.; Hoo, R.L.; Liu, J.; Chow, K.H.; Wang, Y. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury". Hepatology, 2008, 48 (4), 1087-1096.
175. Iwaki, M.; Matsuda, M.; Maeda, N.; Funahashi, T.; Matsuzawa, Y.; Makishima, M.; Shinomura, I. Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptor. Diabetes, 2003, 52, (7), 1655-1663.
176. Maeda, N.; Takahashi, M.; Funahashi, T.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; Kuriyama, H.; Hotta, K.; Nakamura, T.; Shinomua, I.; Matsuzawa, Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 2001, 50 (9), 2094-2099.
177. Malhi, H.; Guicciardi, M.E.; Gores, G.J. Hepatocyte death: a clear and present danger. Physiol. Rev., 2010, 90 (3), 1165-1194.
178. Elsharkawy, A.W.; Oakley, F.; Mann, D.A. The role and regulation of hepatic stellate cells apoptosis in reversal of liver fibrosis. Apoptosis, 2005, 10 (5), 927-937.
179. Viswakarma, N.; Yu, S.; Naik, S.; Kashireddy, P.; Matsumoto, K.; Sarkar, J.; Sarapureddi, S.; Jia, Y.; Rao, M.S.; Reddy, J.K. Transcriptional regulation of Cidea, mithocondrial cell death-inducing DNA fragmentation factor alpha-like effector A, in mouse liver by peroxisome proliferator-activated receptor alpha and gamma. J. Biol. Chem., 2007, 282 (25), 18613-18624.
180. Renga, B.; Mencarelli, A.; Migliorati, M.; Cipriani, S.; D'Amore, C.; Distruttu, E.; Fiorucci, S. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor - γ by the bile acid sensor farnesoid X receptor counter-regulates the proinflammatory phenotype of liver myofibrolasts. Inflamm. Res., 2011, 60, 577-587.
181. Nan, YM.; Fu, N.; Wu, WJ.; Liang, BL.; Wang, RQ.; Zhao, SX.; Zhao, JM.; Yu, J. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand. J. Gastroenterol., 2009, 44 (3), 358-365.
182. Yu, J.; Zhang, S.; Chu, ESH.; Go, MYY.; Lau, RHY.; Zhao, J.; Wu, CW.; Tong, L.; Zhao, J.; Poon, TCW.; Sung, JJY. Peroxisome proliferator activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int. J. Biochem. Cell. Biol., 2010, 42 (6), 948-957.
183. Zhao, C.; Chen, W.; Yang, L.; Chen, L.; Stimpson, SA.; Diehl, AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem. Biophys. Res. Commun., 2006, 350 (2), 385-391.
184. Schaffner, F.; Popper, H. Capillarization of hepatic sinusoid in man. Gastroenterology, 1963, 44, 239-242.
185. Hiukka, A.; Maranghi, M.; Matikainen, N.; Taskinen, M.R. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. Nat. Rev. Endocrinol., 2010, 6, 454-463.
186. Lefebvre, P.; Chinetti, G.; Fruchart, J.C.; Staels, B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest., 2006, 116, 571-580.
187. Han, S.H.; Quon, M.J.; Koh, K.K. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension, 2005, 46, 1086-1092.
188. Rodriguez-Villarupla, A.; Laviña, B.; Carcìa-Calderò, H.; Russo, L.; Rosado, E.; Roglans, N.; Bosch, J.; Garcìa-Pagàn, J.C. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. J. Hepatol., 2012, 56, 1033-1039.
189. Nagula, S.; Jain, D.; Groszmann, R.J.; Garcia-Tsao, G. Histological-hemodynamic correlation in cirrhosis - a histological classification of the severity of cirrhosis. J. Hepatol., 2006, 44, 111-117.
190. Xie, G.; Wang, X.; Wang, L.; Atkinson, R.D., Kanel, G.C.; Gaarde, W.A.; DeLeve, L.D. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology, 2012, 142 (4), 918-927.
191. Olsson, A.K.; Dimberg, A.; Kreuger, J.; CLaesson-Welsh, L. VEGF receptor signalling -in control of vascular function. Nat Rev Mol Cell Biol., 2006, 7, 359-371.
192. Kisseleva, T.; Brenner, D.A. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract. Res. Clin. Gastroenterol., 2011, 25 (2), 305-317.
193. Friedman, S.L.; Bansal, M.B. Reversal of hepatic fibrosis -fact or fantasy?. Hepatology, 2006, 43 (2) S82-S88.
194. Schuppan, D.; Popov, Y. Rationale and targets for antifibrotic therapies. Gastroenterol. Clin. Biol., 2009, 33 (10-11), 949-957.
195. Marra, F.; Aleffi, A.; Galastri, S.; Provenzano, A. Mononuclear cells in liver fibrosis. Semin. Immunopathol., 2009, 31 (3), 345-358.
196. Klein, I.; Cornejo, J.C.; Polakos, N.K.; John, B.; Wuensch, S.A.; Topham, D.J.; Pierce, R.H.; Crispe, I.N. Kupffer cell heterogeneity: functional properties of bone marrow-derived and sessile hepatic macrophages". Blood, 2007, 110 (12), 4077-4085.
197. Bataller, R.; Brenner, D.A. Liver fibrosis. J. Clin. Invest., 2005, 115 (2), 209-218.
198. Parola, M.; Marra, F.; Pinzani, M. Myofibroblast -like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol. Aspects Med., 2008, 29 (1-2), 58-66.
199. Huang, W.; Glass, C.K. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler. Thromb. Vasc. Biol., 2010, 30 (8), 1542-1549.
200. Browning, JD.; Horton, JD. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest., 2004, 114 (2), 147-152.
201. Rakhshandehroo, M.; Hooiveld, G.; Muller, M.; Kersten, S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One., 2009, 4 (8), e6796.
202. Boitier, E.; Gautier, J.C.; Roberts, R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp. Hepatol., 2003, 2 (1), 3.
203. Mounho, B.J.; Thrall, B.D. The extracellular signal-regulated kinase pathway contributes to mitogenic and antiapoptotic effects of peroxisome proliferators in vitro. Toxicol. Appl. Pharmacol., 1999, 159 (2), 125-133.
204. Cosulich, S.C.; James, N.; Roberts, R.A. Role of MAP kinase signalling pathways in the mode of action of peroxisome proliferators. Carcinogenesis, 2000, 21 (4), 579-584.
205. Ip, E.; Farrell, G.C.; Robertson, G.R.; Hall, P.; Kirsch, R.; Leclercq, I.A. Central role of PPARγ-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology, 2003, 38 (1), 123-132.
206. Ip, E.; Farrell, G.C.; Hall, P.; Robertson, G.R.; Leclercq, I.A. Administration of the Potent PPARα Agonist, Wy-14,643, Reverses Nutritional Fibrosis and Steatohepatitis in Mice. Hepatology, 2004, 39 (5), 1286-1296.
207. Jedlitschky, G.; Mayatepek, E.; Keppler, D. Peroxisomal leukotriene degradation: biochemical and clinical implications. Adv. Enzyme. Regul., 1993, 33, 181-194.
208. Fischer, M.; You, M.; Matsumoto, M.; Crabb, D.W. Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARγ dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J. Biol. Chem., 2003, 278 (30), 27997-28004.
209. Schmidt, A.; Endo, N.; Rutledge, S.J.; Vogel, R.; Shinar, D.; Rodan, G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol., 1992, 6 (10), 1634-1641.
210. Fruchart, J.C.; Staels, B.; Duriez, P. The role of fibric acids in atherosclerosis. Curr. Atheroscler. Rep., 2001, 3 (1), 83-92.
211. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98 (19), 2088-2093.
212. Maragoudakis, M.E.; Hankin, H. On the mode of action of lipidlowering agents. V. Kinetics of the inhibition in vitro of rat acetyl coenzyme A carboxylase. J. Biol. Chem., 1971, 246 (2), 348-358.
213. Staels, B.; Vu-Dac, N.; Kosykh, V.A.; Saladin, R.; J.C. Fruchart, J.C.; Dallongeville, J.; Auwerx, J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest., 1995, 95 (2), 705-712.
214. Heller, F.; Harvengt, C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur. J. Clin. Pharmacol., 1983, 25 (1), 57-63.
215. Barter, P.J.; Rye, K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol., 2008, 28 (1), 39-46.
216. Malmendier, C.L.; Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis, 1985, 55 (2), 161-169.
217. Mellies, M.J.; Stein, E.A.; Khoury, P.; Lamkin, G.; Glueck, C.J. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. Atherosclerosis, 1987, 63 (1), 57-64.
218. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A.T.; Neve, B.; Torra, I.P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H.B.; Fruchart, J.C.; Clavey, V.; Staels, B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7 (1), 53-58.
219. Mardones, P.; Pilon, A.; Bouly, M.; Duran, D.; Nishimoto, T.; Arai, H.; Kozarsky, K.F.; Altayo, M.; Miquel, J.F.; Luc, G.; Clavey, V.; Staels, B.; Rigotti, A. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. J. Biol. Chem., 2003, 278 (10), 7884-7890.
220. Manninen, V.; Tenkanen, L.; Koskinen, P.; Huttunen, J.K.; Manttari, M.; Heinonen, O.P.; Frick, M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 1992, 85 (1), 37-45.
221. Ikewaki, K.; Tohyama, J.; Nakata, Y.; Wakikawa, T.; Kido, T.; Mochizuki, S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men -a nuclear magnetic resonance study. J. Atheroscler. Thromb., 2004, 11 (5), 278-285.
222. Pauciullo, P.; Marotta, G.; Rubba, P.; Cortese, C.; Caruso, MG.; Gnasso, A.; Fischetti, A.; Motti, C.; Mancini, M. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia. J. Intern. Med., 1990, 228 (5), 425-430.
223. Nanji, A.A.; Dannenberg, A.J.; Jokelainen, K.; Bass, N.M. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-α (PPARα)-regulated genes and is ameliorated by PPARα activation. J. Pharmacol. Exp. Ther., 2004, 310 (1), 417-424.
224. Boshra, V.; Moustafa, A.M. Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-a ligand, on hepatic ischemia-reperfusion injury in rats. J. Mol. Histol., 2011, 42 (2), 113-122.
225. Zuniga, J.; Cancino, M.; Medina, F.; Varela, P.; Vargas, R.; Tapia, G.; Videla, L.A.; Fernandez, V. N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-kB interaction: antiinflammatory implications in liver ischemia-reperfusion injury. PLoS. One, 2011, 6 (12), e28502.
226. Ban, S.; Kasuga, J.; Nakagome, I.; Nobusada, H.; Takayama, F.; Hirono, S.; Kawasaki, H.; Hashimoto, Y.; Miyachi, H. Structurebased design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferatoractivated receptor (PPAR)α-selective agonists. Bioorg. Med. Chem., 2011, 19 (10), 3183-3191.
227. Risérus, U.; Sprecher, D.; Johnson, T.; Olson, E.; Hirschberg, S.; Liu, A.; Fang, Z.; Hegde, P.; Richards, D.; Sarov-Blat, L.; Strum, JC.; Basu, S.; Cheeseman, J.; Fielding, B.A.; Humphreys, S.M.; Danoff, T.; Niall, R.; Moore, N.R.; Murgatroyd, P.; O'Rahilly, S.; Sutton, P.; Willson, T.; Hassall, D.; Frayn, K.N.; Karpe. F. Activation of Peroxisome Proliferator-Activated Receptor (PPAR)δ promotes reversal of multiplemetabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes, 2008, 57 (2), 332-339.
228. Lee, C.H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L.W.; Olefsky, J.M.; Gonzalez, F.J.; Ham, J.; Kang, H.; Peters, J.M.; Evans, R.M. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U S A, 2006, 103 (9), 3444-3449.
229. Chen, W.; Wang, L.L.; Liu, H.Y.; Long, L.; Li, S. Peroxisome Proliferator-Activated Receptor δ-Agonist, GW501516, Ameliorates Insulin Resistance, Improves Dyslipidaemia in Monosodium L-Glutamate Metabolic Syndrome Mice. Basic Clin. Pharmacol. Toxicol., 2008, 103 (3), 240-246.
230. Seedorf, U.; Aberle, J. Emerging roles of PPARδ in metabolism. Biochim. Biophys. Acta., 2007, 1771 (9), 1125-1131.
231. Leibowitz, M.D.; Fiévet, C.; Hennuyer, N.; Peinado-Onsurbe, J.; Duez, H.; Bergera, J.; Cullinan, C.A.; Sparrow, C.P.; Baffic, J.; Berger, G.D.; Santini, C.; Marquis, R.W.; Tolman, R.L.; Smith, R.G.; Moller, D.E.; Auwerx, J. Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS. Lett., 2000, 473 (3), 333-336.
232. Pang, M.; de la Monte, S.M.; Longato, L.; Tong, M.; He, J.; Chaudhry R.; Duan K.; Ouh J.; Wands J.R. PPARδ agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J. Hepatol., 2009, 50 (6), 1192-1201.
233. Shan, W.; Nicol, C.J.; Ito, S.; Bility, M.T.; Kennet, M.J.; Ward, J.M.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. Hepatology, 2008, 47 (1), 225-235.
234. Iwaisako, K.; Haimerl, M.; Paik, Y.H.; Taura, K.; Kodama, Y.; Sirlin, C.; Yu, E.; Yu, R.T.; Downes, M.; Evans, R.M.; Brenner, D.A.; Schnabl, B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc. Nat. Acad. Sci. U S A, 2012, 109 (21), E1369-E1376.
235. Kasuga, J.; Nakagome, I.; Aoyama, A.; Sako, K.; Ishizawa, M.; Ogura, M.; Makishima, M.; Hirono, S.; Hashimoto, Y.; Miyachi, H. Design, synthesis and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists. Bioorg. Med. Chem., 2007, 15 (15), 5177-5190.
236. Han, J.; Hajjar, DP.; Tauras, JM.; Feng, J.; Gotto, AM. Jr.; Nicholson, AC. Transforming growth factor-beta1 (TGF-beta1) and TGFbeta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J. Biol. Chem., 2000, 275 (2), 1241-1246.
237. Wu, Z.; Xie, Y.; Morrison, R.F.; Bucher, N.L.; Farmer, S.R. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest., 1998, 101 (1), 22-32.
238. Baumann, C.A.; Chokshi, N.; Saltiel, A.R.; Ribon, V. Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene. J. Biol. Chem., 2000, 275 (13), 9131-9135.
239. Thompson, A.J.; Patel, K. Antifibrotic therapies: will we ever get there? Curr. Gastroenterol. Rep., 2010, 12 (1), 23-29.
240. Lee, J.I.; Paik, Y.H.; Lee, K.S.; Lee, J.W.; Kim, Y.S.; Jeong, S.; Kwon, K.S.; Lee, D.H.; Kim, H.G.; Shin, Y.W.; Kim, M.A. A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells. Histochem. Cell. Biol., 2007, 127 (5), 495-502.
241. Rogue, A.; Spire, C.; Brun, M.; Claude, N.; Guillouzo, A. Gene expression changes induced by PPARγ agonist in animal and human liver. PPAR. Res., 2010, 2010: 325183.
242. Yuan, G.J.; Zhang, M.L.; Gong, Z.J. Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World. J. Gastroenterol., 2004, 10 (7), 1047-1051.
243. Nan, Y.M.; Han, F.; Kong, L.B.; Zhao, S.X.; Wang, R.Q.; Wu, W.J.; Yu, J. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand. J. Gastroenterol., 2011, 46 (3), 358-369.
244. Chen, H.; He, Y.W.; Liu, W.Q.; Zhang, J.H. Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum. World. J. Gastroenterol., 2008, 14 (18), 2905-2911.
245. Rogue, A.; Lambert, C.; Josse, R.; Antherieu, S.; Spire, C.; Claude, N.; Guillouzo, A. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. PLoS. One, 2011, 6 (4), Article e18816.
246. Yang, L.; Stimpson, S.A.; Chen, L.; Harrington, W.W.; Rockey, D.C. Effectiveness of the PPARγ agonist, GW570 in liver fibrosis. Inflamm. Res., 2010, 59 (12), 1061-1071.
247. Sun, K.; Wang, Q.; Huang, X.H. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta. Pharmacol. Sin., 2006, 27 (6), 715-723.
248. Bae, M.A.; Rhee, S.D.; Jung, W.H.; Ahn, J.H.; Song, B.J.; Cheon, H.G. Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776. Arch. Pharm. Res., 2010, 33 (3), 433-442.
249. 2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor γ-inducing drugs. Liver. Int., 2009, 29 (5), 730-735.
250. 2 inhibits fibrogenic response in human hepatoma cells. Toxicol. Lett., 2009, 187 (1), 22-27.
251. Han, Z.; Zhu, T.; Liu, X.; Li, C.; Yue, S.; Liu, X.; Yang, L.; Yang, L.; Li, L. 15-Deoxy-Δ (12,14)-prostaglandin J(2) reduces recruitment of bone marrow-derived monocyte/macrophages in chronic liver injury in mice. Hepatology, 2012, 56 (1), 350-360.
252. Sharma, R.A.; Steward, W.P.; Gescher, A.J. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol., 2007, 595, 453-470.
253. Park, E.J.; Jeon, C.H.; Ko, G.; Kim, J.; Sohn, D.H. Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J. Pharm. Pharmacol., 2000, 52 (4), 437-440.
254. Singh, S.; Aggarwal, B.B. Activation of transcription factor NF-kB is suppressed by curcumin (diferuloylmethane). J. Biol. Chem., 1995, 270 (42), 24995-5000.
255. Abe, Y.; Hashimoto, S.; Horie, T. Curcumin inhibition of inflammatory cytokine production by human peripherals blood monocytes and alveolar macrophages. Pharmacol. Res., 1999, 39 (1), 41-47.
256. 4 in rats: role of TGF-b modulation and oxidative stress. Fundam. Clin. Pharmacol., 2008, 22 (4), 417-427.
257. Xu, J.; Fu, Y.; Chen, A. Activation of peroxisome proliferatoractivated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am. J. Physiol. Gastrointest. Liver. Physiol., 2003, 285 (1), G20-G30.
258. Huang, T.; David, L.; Mendoza, V.; Yang, Y.; Villarreal, M.; De, K.; Sun, L.; Fang, X.; López-Casillas, F.; Wrana, JL.; Hinck, AP. TGF-β signalling is mediated by two autonomously functioning TβRI:TβRII pairs. EMBO J., 2011, 30 (7), 1263-1276.
259. Zheng, S.; Chen, A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem. J., 2004, 384 (pt. 1), 149-157.
260. Zheng, S.; Chen, A. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290 (5), G883-G893.
261. Zheng, S.; Chen, A. Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator- activated receptor-gamma in rat hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292 (1), G113-G123.
262. 4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol., 2008, 73 (2), 399-409.
263. Zhou, Y.; Zheng, S.; Lin, J.; Zhang, Q.J.; Chen, A. The interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARgamma in rat activated hepatic stellate cell in vitro. Lab. Invest., 2007, 87 (5), 488-498.
264. Lin, J.; Chen, A. Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab. Invest., 2008, 88 (5), 529-540.
265. Baghdasaryan, A.; Claudel, T.; Kosters, A.; Gumhold, J.; Silbert, D.; Thuringer, A.; Leski, K.; Fickert, P.; Karpen, S.J.; Trauner, M. Curcumin improves sclerosing cholangitis in Mdr2-/-mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut, 2010, 59 (4), 521-530.
266. Vizzuti, F.; Provenzano, A.; Galastri S.; Milani S.; Delogu W.; Novo E.; Caligiuri A.; Zamara E.; Arena, U.; Laffi, G.; Parola, M.; Pinzani, M.; Marra, F. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab. Invest., 2010, 90 (1), 104-115.
267. Bassiouny, A.R.; Zaky, A.; Fawky, F.; Kandeel, K.M. Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann. Hepatol., 2011, 10 (4), 516-530.
268. Wang, M.E.; Chen, Y.C.; Chen, I.S.; Hsieh, S.C.; Chen, S.S.; Chiu, C.H. Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. J. Nutr. Biochem., 2012, 23(10), 1352-1366.
269. Ohashi, M.; Oyama, T.; Nakagome, I.; Sato, M.; Nishio, Y.; Nobusada, H.; Hirono, S.; Morikawa, K.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and structural analysis of phenylpropanoic acidtype PPARγ-selective agonists: Discovery of reversed stereochemistry-activity relationship. J. Med. Chem., 2011, 54 (1), 331-341.
270. Lin, J.; Tang, Y.; Kang, Q.; Feng, Y.; Chen, A. Curcumin inhibits advanced glycationend-products (AGEs)-induced gene expression of receptor for AGEs (RAGE) in hepaticstellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br. J. Pharmacol., 2012, 166 (8), 2212-2227. DOI: 10.1111/j.1476-5381.2012.
271. Festa, C.; Lauro, G.; De Marino, S.; D'Auria, M.V.; Monti, M.C.; Casapullo, A.; D'Amore, C.; Renga, B.; Mencarelli, A.; Petek, S.; Bifulco, G.;
272. Tenenbaum, A.; Motro, M.; Fisman, E.Z. Dual and pan-peroxisome proliferator activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol., 2005, 4, 14.
273. Li, P.P.; Shan, S.; Chen, Y.T.; Ning, Z.Q.; Sun, S.J.; Liu, Q.; Lu, X.P.; Xie, M.Z.; Shen, Z.F. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br. J. Pharmacol., 2006, 148 (5), 610-618.
274. Mishra, P.; Younossi, Z.M. Current treatment strategies for nonalcoholic fatty liver disease (NAFLD). Curr. Drug. Discov. Technol., 2007, 4 (2), 133-140.
275. Sasaki, Y.; Shimada, T.; Iizuka, S.; Suzuki, W.; Makihara, H.; Teraoka, R.; Tsuneyama, K.; Hokao, R.; Aburada, M. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur. J. Pharmacol., 2011, 662 (1-3), 1-8.
276. Jin, L.; Lin, S.; Rong, H.; Zheng, S.; Jin, S.; Wang, R.; Li, Y. Structural basis for iloprost as a dual peroxisome proliferatoractivated receptor α/δ agonist. J. Biol. Chem., 2011, 286 (36), 31473-31479.
277. Moncada, S.; Gryglewski, R.; Bunting, S.; Vane, J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature, 1976, 263 (5579), 663-665.
278. Fennekohl, A.; Schieferdecker, H.L.; Jungermann, K.; Püschel, GP. Differential expression of prostanoid receptors in hepatocytes, Kupffer cells, sinusoidal endothelial cells and stellate cells of rat liver. J. Hepatol., 1999, 30 (1), 38-47.
279. Zardi, E.M.; Picardi, A.; Ambrosino, G.; Serio, A.; Costantino, S.; Dobrina, A. Hemodynamic effects of a prostacyclin analog (iloprost) on portal flow velocity and volume and visceral artery circulation in patients with lower limb arteriopathy. Ultrasound. Med. Biol., 2003, 29 (2), 209-213.
280. Tanaka, J.; Malchesky, P.S.; Omokawa, S.; Goldcamp, J.B.; Harasaki, H.; Vogt, D.P.; Broughan, T.A.; Nosé Y. Effects of prostaglandin I2, superoxide dismutase, and catalase on ischemiareperfusion injury in liver transplantation. ASAIO. Trans., 1990, 36 (3), M600-M603.
281. Okboy, N.; Yegen, C.; Aktan, A.O.; Dosluoglu, H.H.; Sav, A.; Yalin, R.; Ercan, S. The effect of iloprost and NDGA in ischemia reperfusion injury in rat liver. Prostagl. Leukotr. Essential Fatty. Acids., 1992, 47 (4), 291-295.
282. Takayama, F.; Egashira, T.; Kawasaki, H.; Mankura, M.; Nakamoto, K.; Okada, S.; Mori, A. A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH. J. Clin. Biochem. Nutr., 2009, 45 (2), 335-340.
283. Caraceni, P.; Ryu, H.S.; Subbotin, V.; De Maria, N.; Colantoni, A.; Roberts, L.; Trevisani, F.; Bernardi, M.; Van Thiel, D.H. Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury. Hepatology, 1997, 25 (4), 943-949.
284. Zardi, E.M.; Dobrina, A.; Amoroso, A.; Afeltra, A. Prostacyclin in liver disease: a potential therapeutic option. Expert. Opin. Biol. Ther., 2007, 7 (6), 785-790.
285. Zardi, E.M.; Zardi, D.M.; Cacciapaglia, F.; Dobrina, A.; Amoroso, A.; Picardi, A.; Afeltra, A. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. Int. Immunopharmacol., 2005, 5 (3), 437-459.
286. Zardi, E. M.; Picardi, A.; Fazio, V. M.; Ambrosino, G.; Dobrina, A.; Zullo, M.; Zennaro, D.; Afeltra, A. Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection: a pilot study with possible therapeutic implications. J. Interferon. Cytokine. Res., 2004, 24 (5), 297-300.
287. Adeghate, E.; Adem, A.; Hasan, M. Y.; Tekes, K.; Kalasz, H. Medicinal chemistry and actions of dual and pan PPAR modulators. Open. Med. Chem. J., 2011, 5 (suppl2-M5), 93-98.
288. Oyama, T.; Toyota, K.; Waku, T.; Hirakawa, Y.; Nagasawa, N.; Kasuga, J-I.; Hasimoto, Y.; Miyachi, H.; Morikawa, K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta. Crystallogr. D. Biol. Crystallogr., 2009, 65 (8), 786-795.
289. Kuwabara, N.; Oyama, T.; Tomioka, D.; Ohashi, M.; Yanagisawa, J.; Shimizu, T.; Miyachi, H. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. J. Med. Chem., 2012, 55 (2), 893-902.